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ABSTRACT
The thiol protease inhibitor (TPI—d) from hindlimb 
skeletal muscle of 60 day old dystrophic male mice (strain 
129/ReJ—dy) and thiol protease inhibitor (TPI—h) from the 
skeletal muscle of 9 months old carrier females, heterozygous 
for the disease, have been purified to apparent homogeneity 
and compared with the thiol protease inhibitor (TPI—n) from 60 
day old normal male 1ittermates and thiol protease inhibitor 
(TPI—c) from 9 month old normal retired breeders. While 
TPI—d, TPI—n, TPI—h and TPI—c all displayed identical 
properties on SDS—polyacrylamide gels (Mr 14,800), analytical 
isoelectric focusing gels (pi 4.5), and high performance 
liquid chromatography columns, TPI—d was unable to inhibit 
papain and cathepsin B after purification by isoelectric 
focusing. However, a component in the apparently purified 
TPI—d preparation with a pi of 4.9 masked the functional state 
of TPI—d when papain or cathepsins H and L were used as test 
proteases. This inhibitory component was also observed in the 
TPI-h preparation from carrier females. However, TPI-h 
inhibits cathepsin B activity to the extent observed with 
inhibitor preparations from normal muscle. The inhibitory 
component of pi 4.9 was absent from TPI—n and TPI—c 
préparâtions. Pure TPI—d was also unable to inhibit myosin 
hydrolysis i.n_yitrg by cathepsin B, whereas TPI—n completely 
blocked cathepsin B catalyzed myosin hydrolysis. Given the 
central role of the thiol proteases, especially cathepsin B, 
in intracellular protein metabolism, and the possibility that
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
uncontrolled thiol .protease activity in muscle leads to muscle 
protein breakdown and dystrophy, this study suggests that the 
thiol protease inhibitor in dystrophic mouse muscle (TPI—d) 
may be (one of) the end—product(s) of the dystrophy gene in 
mice with the hereditary form of the disease.
V I
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I. INTRODUCTION 
The metabolic disorders known as muscular dystrophies 
are a heterogeneous group of disorders characterised by muscle 
weakness and degeneration (Knudson, 1965). Muscular
dystrophies are regarded as primary myopathies; the lesion(s) 
is(are) presumed to be present and expressed in the muscle 
itself (Perry, 1984). Dystrophic tissues exhibit a gradual 
deterioration of function associated with progressive necrosis 
and often, in the early stages of the disease, certain muscles 
which are characteristic of the type of dystrophy, are 
specifically affected. One of the most severe forms of the 
disease is the X—linked form known as Duchenne muscular 
dystrophy (DMD) which affects mainly young males. The DMD 
locus in humans is at position Xp 21 on the X—chromosome 
(Jacobs et al., 1981). In humans the disease is usually 
diagnosed clinically by about age 3—5, while in mice and 
chickens the expression of the disease begins around 2—3 weeks 
ex—utero (Walton and Nattras, 1954). Histological 
examinations of muscle in the early stages of Duchenne 
muscular dystrophy have revealed differences in the 
organization of the contractile elements compared to normal 
muscle. As the disease progresses many muscle fibres show 
extensive degeneration, the sarcolemma shows areas of 
discontinuity and there is a disproportionate increase in 
connective tissue and fat cells in severely affected muscle 
(Cazzato, 1968; Hunters, 1980). Numerous other morphological 
changes have been reported in the various forms of dystrophy
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
(Cullen and Mastaglia, 1980).
During the past 20 years several hypotheses have been 
advanced to explain the pathogenesis of muscle in laboratory 
animals and Duchenne muscular dystrophy patients. These 
include the vascular hypothesis (Sweeney and Brown, 1981), 
neurogenic theory (Desmos, 1961), membrane theory (McComas et 
al. 1978), myogenetic theory (Witkowski and Jones, 1981) and 
connective tissue theory (Lucy, 1980). While there are 
abundant experimental data to support each of these views, it 
is not yet clear whether the observations which led to these 
hypotheses are primary or secondary process(es) of the 
disease. The biochemical nature of muscular dystrophy is 
poorly understood. Thus the cause(s) of the myriad of 
biochemical alterations which occur(s) in dystrophic animals 
has(have) not been identified.
A. yse_gf_animal_mgdels_tg_study_the_disease_Brgçess
A disease in experimental animals which simulates both 
morphologically and clinically a disease process in humans, 
does not indicate, a priori, that the etiology or pathology of 
the experimental animal and human disease are the same (Bajusz 
et al., 1966). The value of the experimental model in 
elucidating the etiology and pathogenesis of human diseases 
becomes apparent only when it can be shown that the responses 
to a variety of stimuli of animal/tissue under investigation 
are identical or similar to that in the human. Differences in 
tissue response per se indicate a difference in pathogenesis
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
and warn the investigator of the degree of its possible 
existence (Bajusz et al., 1966). Therefore the greater the 
difference in response, both clinically and morphologically 
between the experimentally induced disease and the disease in 
humans, the greater the likelihood of etiological and 
pathogenetic differences. By the intelligent use of 
experimental models and a variety of experimental techniques, 
the possibility exists that greater insight into human disease 
processes may be obtained. Despite the fact that inherited 
forms of muscular dystrophy were first described in the mouse 
and chicken more than 4 decades ago, and in the hamster in 
1962, the debate continues regarding their relevance to human 
forms of muscular dystrophy (Mendel1 et al., 1979; Watts and 
Reid, 1969; Bradley and Jenkinson, 1975 ; Johnson and 
Montgomery, 1976; Jasmin and Bokdawala, 1970). The 
controversy will probably continue until specific biochemical 
defects are identified which can be used as a basis for 
comparison between human and animal forms of muscular 
dystrophy.
B. Murine muscular dustrophu
Murine Muscular dystrophy was first observed as a 
spontaneous autosomal mutation in strain 129/ReJ (Michelson et 
al., 1955) causing muscular weakness, atrophy and reduced life 
span characteristic of myopathy. In mice there are a number 
of clinical, histological and pathological similarities to DMD 
in humans, except for the difference in inheritance, which is
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
autosomal. Clinically, dystrophic mice can be identified by 
their abnormal behaviour at about 2 weeks of age. Clinical 
signs are muscular weakness, periodic dragging of the rear 
feet, clasping of the hindlimbs when the animal is suspended, 
and spasmodic gaping or nodding of the head (Russell, 1961). 
Also, the dystrophic mice are much smaller than their normal 
litter mates (see Fig la) and the leg muscles weigh about one 
half that of the normal mice (Gopalan et al., 1986a). Fig. lb 
shows the leg musculature of normal and dystophic mice. In 
certain stocks, afflicted animals often show tetanic 
seizures which are not usually lethal. If dystrophic mice 
live long enough, they develop permanent paralysis of hind 
limbs and severe contractures. Very old dystrophic mice often 
develop and die of pneumonia (Russel and Meier, 1979).
Extensive investigations have defined structural 
details of muscle fibre breakdown in murine dystrophy (Platzer 
and Powell, 1975). According to Platzer and Powell the 
earliest identifiable ultrastructural change is seen in the 
sarcoplasmic reticulum which becomes dialated. This change is 
fallowed sequentially by the appearance of fragmented 
myofibrils which are out of register, and swollen spherical 
mitochondria which contain irregularities in the cristae and 
some electron dense areas in the matrix. With continued 
muscle fibre breakdown, the fibres show retraction clots, 
sparsity of cellular organelles, including the T—system, 
myofibrillar fragmentation and further sarcolemmal breakdown, 
leading finally to phagocytic infiltration.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Figure la. Photograph of normal and dystrophic mice. Note
the reduced size of the dystrophic mouse (right)
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Figure lb. Photograph showing the hind leg muscles of
normal and dystrophic mice.
Top: Hind leg muscles from normal mouse.
Bottom: Hind leg muscles from dystrophic mouse.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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In the mouse, the individual pattern of muscle fibre 
breakdown occurs in an entirely different setting than that 
seen in the hamster (Mendel1 et al., 1979). The degenerating 
fibres are usually randomly distributed as either isolated 
fibres or as two or three together. There are, however, areas 
of the muscle that display preferential involvement in the 
process. In the 129/ReJ dy/dy strain, the crown position of 
the anterior tibialis, composed of predominantly fast twitch 
glycolytic fibres, appears to be the site of primary 
expression of the disease. In C57BL/dy^*^/dy^*^ strain, the 
target is believed to be the slow twitch oxidative fibres of 
the core portion of the anterior tibialis and soleus muscles.
The initial stage of muscle fibre breakdown appears to 
involve partial or complete segments of muscle fibres. These 
areas of the muscle fibre are then invaded by macrophages. 
Before phagocytosis is complete, evidence of muscle fibre 
regeneration ensues with the appearance of presumptive 
mononuclear myoblasts, which apparently fuse to form 
regenerating fibres (West and Murphy, 1960).
It is during the latter stage of regenerative activity 
that murine dystrophy shows singular differences from the 
hamster form of the disease. In association with the muscle 
fibre régénérâtion, proliferation of the endomysial connective 
tissue is quite prominent. West and Murphy (1960) describe 
this phenomenon as an "early sequela to regenerative activity" 
which they believe is the result of newly proliferated 
connective tissue rather than condensation of existing
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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endomysium. The final stages of murine dystrophy are 
characterised by marked variability in muscle fibre size, and 
significant endomysial connective tissue proliferation, which 
surrounds smaller diameter fibres. Fatty replacement is not a 
prominent feature; however, it can be enhanced by prolonging 
the life span of the animal (Mendel1 et al., 1979).
C. ÇgmBarisgn_of_dystrgBhy_in_miçe_and_humans
In humans, in yitrg studies show that the early stages 
of muscle fibre breakdown are associated with extensive 
leakage of horseradish peroxidase into muscle fibres (Mendel1 
et al., 1979). The small wedge-shaped pattern of horseradish 
peroxidase leakage observed in hamster and Duchenne human 
dystrophy is not seen in murine dystrophy. However, in the 
mouse, horseradish peroxidase infiltration is usually more 
extensive, suggesting that larger segments of the plasma 
membrane are affected during muscle fibre dégénérâtion. This 
conclusion is consistent with previous ultrastructural reports 
on mouse dystrophy which describe alterations in sarcoplasmic 
organelles prior to breakdown of the cell membrane (Platzer 
and Powell, 1975). Accumulation of calcium deposits and other 
signs of cell damage support the conclusion that focal defects 
in the plasma membrane are probably not the initial events in 
cellular degeneration in murine dystrophy. However, 
identification of both horseradish peroxidase leakage and 
calcium influx during early cellular necrosis (prior to 
phagocytosis) may have relevance to the pathogenesis of muscle
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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fibre breakdown in some types of human muscular dystrophies,
D. Syrian_hamster_^stroBhy
Syrian hamsters suffering from hereditary muscular 
dystrophy develop acute cardiac muscle lesions in addition to 
skeletal muscle breakdown. The acquisition of knowledge 
concerning involvement of the heart in progressive muscular 
dystrophy, and in other forms of primary myopathies is 
important from several viewpoints. Ignorance of this subject 
may lead not only to incorrectly identified clinical symptoms, 
but also to inaccurate etiological diagnosis and treatment. 
From a pathophysiological viewpoint, cardiac involvement is of 
great interest in respect to both its haemodynamic effect per 
se and the underlying mechanisms of heart failure.
Furthermore, studies of this type of cardiac condition provide 
an opportunity to gain information concerning differences in 
susceptibility between cardiac and skeletal muscles, since 
virtually nothing is known about the factors that determine 
which of these two muscle systems will undergo degeneration in 
any given set of pathological circumstances (Bajusz et al., 
1966). From a biochemical viewpoint, an analysis of the 
altered myocardial metabolism may elucidate the primary 
biochemical lesion responsible for the disease in striated 
muscles. In view of these considerations, studies of cardiac 
muscle lesions which develop in 100% of the Syrian hamsters 
suffering from hereditary muscular dystrophy become important.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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In a large percentage of these animals (ca. 90%), cardiac 
involvement progresses to congestive heart failure. The gross 
and histopathological abnormalities seen outside the skeletal 
and cardiac muscles in the myopathic hamsters are consistent 
with chronic passive venous congestion, and the progressive 
cardiovascular insufficiency may be regarded as the ultimate 
cause of death. Thus, the inbred line of Syrian hamsters 
provides not only an opportunity to study the involvement of 
the cardiovascular system in a genetically determined primary 
myopathy, but it also presents a useful and unique disease 
model for analysis of the underlying mechanism of congestive 
heart failure. The slow progression of the cardiovascular 
condition in the myopathic hamsters and high incidence of 
congest ive heart failure within the homozygous line offers new 
possibilities for investigative cardiology.
The initial stages of individual skeletal muscle fibre 
breakdown are characterised by a series of changes in the 
myofilaments and mitochondria. Under the light microscope the 
mitochondria appear swollen and often clumped together, and 
the muscle fibres have lost their normal striations usually 
appearing hyalinized or hypercontracted. This stage is soon 
followed by the presence of macrophages surrounding and 
finally invading the fibre (Mendel1 et al., 1979). At the 
ultrastructural level, the mitochondria display a spectrum of 
changes accompanying the early events. The clumping of 
mitochondria seen in the light microscope is quite apparent. 
The mitochondria become spherical rather than elongated in
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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appearance and they are often larger than normal. The cristae 
are indistinct or absent in some mitochondria, while in others 
they exhibit parallel and concentric arrays. Concommitent 
with histological changes, myofilaments ultimately become more 
fragmented and randomly oriented. Initially, the A bands are 
preferentially spared, while there is a complete absence of 
the Z bands. Accompanying the initial stages of muscle fibre 
breakdown, but proceeding phagocytosis, are intracellular 
accumulations of granular material seen with alizarin red 
stain for calcium (Mendel1 et al., 1979). Some fibres 
demonstrate granular deposits restricted to the subsarcolemmal 
regions while in others, calcium deposits are observed to be 
distributed throughout the cross sectional diameter of the 
fibre (Mendel 1 et al., 1979).
Various stages of horseradish peroxidase leakage into 
muscle fibres were observed corresponding to the stages of 
muscle fibre breakdown. The earliest detectable change that 
preceded phagocytosis was leakage into the subsarcolemmal 
region, which could be seen in the light and electron 
microscope. The area of leakage was often restricted to a 
small wedge shaped area with the base toward the periphery or 
in the form of a restricted subsarcolemmal band of horseradish 
peroxidase. The area of wedge shaped leakage displayed a loss 
of overlying plasma membrane with preservation of the basement 
membrane. In advanced stages of muscle fibre breakdown, 
leakage of horseradish peroxidase extended further into the 
sarcoplasm (Mendel1 et al., 1979).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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E. ÇomBarisgn.gf_dustrBBhu_in_hamsters_aDd_humaQi
The initial stages of skeletal muscle fibre breakdown in 
the hamster have certain similarities to Duchenne muscular 
dystrophy (Mokri and Engel, 1975; Bodensteiner and Engel, 
1977). The early leakage of horseradish peroxidase in a 
wedge-shaped pattern in the muscle fibre is similar to that 
described by Mokri and Engel in humans (1975). This finding 
suggests that the plasma membrane is disrupted as one of the 
early morphological events in muscle fibre breakdown in the 
hamster. This occurence is different from that observed in 
Duchenne muscular dystrophy where the breakdown of the plasma 
membrane accompanies, rather than precedes, other alterations 
in the muscle fibre (Mendel1 et al., 1979). The early 
accumulation of calcium deposits in the muscle fibre is also 
similar to that found in Duchenne dystrophy (Bodensteiner and 
Engel, 1977). A significant distinguishing feature, however,
is that groups of muscle fibres rich in calcium deposits are 
far more extensive in the hamster, and overt mineralization of 
the mitochondria is not a prominent feature of human 
dystrophy.
Several additional points of morphological differences 
from human dystrophy have been observed in the hamster.
Groups of muscle fibres undergoing necrosis and regeneration 
have been seen in Duchenne muscular dystrophy (Karpati et al..
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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1974), but they never reach the extensive size seen in the 
hamster where they can often be visualized grossly (liende11 et 
al., 1979). Furthermore, the marked degree of phagocytosis in 
the hamster is a far more subtle feature in human dystrophy.
In addition, the presence of intracristal plates in the 
mitochondria of degenerating fibres in the hamster are rarely 
seen in Duchenne dystrophy (Karpati et al., 1974). The final 
point, and one that more clearly distinguishes the dystrophic 
process in the hamster from that in humans (aside from the 
fact that dystrophy affects primarily the cardiac muscle in 
hamsters) is the absence of endomysial connective tissue
proliteration and fat infiltration in the hamster. The 
degenerative process in the hamster simply does not seem to 
reach this stage (Mendel1 et al., 1979).
F. Muscular_dystroBhy_in_the_çhiçkens
Myopathy in chickens is characterized principally by a 
failure in the development of fast twitch glycolytic fibres in 
the pectoral is muscles shortly after hatching (Cosmos and 
Butler, 1967). This developmental failure may occur through an 
inability to respond to neurotropic influences mediated by a 
defective sarcolemma. However, evidence that the fetal spinal 
cord imprints a dystrophic character on the pectoral is muscle 
at a very early stage has also been obtained (Rathbone et al.,
1975). A rapid reversal of metabolic behaviour to a fetal 
fibre type occurs during the first 2 weeks ex—gyg. 
Subsequently, the pectoral is displays a marked pseudo—
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hypertrophy, phagocytosis of individual fibres and an increase 
in connective adipose tissue (Owens, 1979).
Horseradish peroxidase studies in dystrophic chicken 
muscle showed that the vacuoles in the individual muscle 
fibres, studied by light and electron microscopy, communicate 
with the extracellular spaces. The limiting membrane, 
distinct in some places, usually could not be traced around 
the entire vacuole. In addition, the foci of the myofibrillar 
disarray begin rather abruptly. The Z-band material appears 
as an irregularly dispersed mass, but the Z—band streaming is 
not seen. The boundaries of A and I bands can be discerned, 
and the thick and thin filaments are completely disoriented. 
There are no obvious organelle changes to give a clue to the 
pathogenesis. Muscle fibres that demonstrate myofibrillar 
disarray do not show any evidence of horseradish peroxidase 
leakage across the membrane (Mendel1 et al., 1979).
6. ÇonjEar i son _of _dys t r QBhy_ i n_çh i çkens_an d_humans
The muscle fibres in dystrophic chickens contain a marked 
increase in lipid droplets. Several abnormalities like 
variation in muscle fibre size, muscle fibre splitting, 
increase in the number of internal nuclei, vacuolization of 
fibres and scattered fibres undergoing necrosis and 
phagocytosis are also seen (Mendel1 et al., 1979). In the 
chicken there is no evidence in support of a significant 
plasma membrane defect, either by horseradish peroxidase 
leakage or by accumulation of calcium deposits, as one of the
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causes for these known abnormalities. In this way, dystrophy 
in chicken muscle shows changes unlike those observed in the 
DMD disorder, where the influx of calcium apparently is the 
stimulus for the muscle fibre to undergo a series of 
morphological changes.
H. Summary_gf_mgrBhglggiçal_çhanges_in_dystrgghiç_animais 
cgmBared_tg_dystrgBhiç_humans 
The hamster and mouse show changes of potential relevance 
toward understanding the pathogenesis of individual muscle 
fibre breakdown in human DMD. In both species, horseradish 
peroxidase leakages and calcium deposits accompany muscle 
fibre breakdown. The chicken, in contrast, offers the 
challenge of understanding the vast array of morphological 
changes in the absence of a significant plasma membrane defect 
as a step in the development of these changes. While perhaps 
no animal disease model can be expected to be identical in 
every way to a human disease, each has features that are 
important in relationship to particular aspects of human 
muscle pathology. Furthermore, the inherited form of muscular 
dystrophy in animals provides a unique opportunity to study 
sequential morphological changes in the development of this 
pathological process.
I. Biochemical_characteriStics_of_dygtrgBhy
The primary biochemical lesions involved in muscular
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dystrophy are not known, although, a great deal of research 
has been done during the last few years. Changes in lipids 
(Hughes, 1972), carbohydrate (Johnson et al., 1979), purines 
(Thomson and Smith, 1978), and protein metabolism (lodice et 
al., 1972; Strickland et al., 1979) have been implicated in 
the onset of dystrophy. Other workers have shown that both RNA 
content and synthesis are increased in dystrophic muscles of 
the mouse (Srivastava, 1968; 1967; Girkin et al., 1962; Fowler 
et al., 1977). However, the RNA content was found to be 
decreased relative to the DNA content (Hayashi et al., 1975). 
Fowler et al.(1977) observed an increase in DNA content in 
dystrophic muscle of the mouse. The significance of increased 
RNA and DNA levels in dystrophic muscle is difficult to 
understand. However, these increases may be due, in part, to 
muscle hypertrophy, which, in turn, reflects the compensatory 
attempts of dystrophic muscle.
Progressive muscular dystrophy is characterised by severe 
wasting of skeletal muscle and this is confirmed by the lower 
body and muscle weights of dystrophic animals (Hayashi et al., 
1975; Watts and Reid, 1969); Kitchin and Watts, 1973). In 
view of the great importance of proteins in the structure and 
function of muscle, many laboratories have studied protein 
metabolism in dystrophic animals. Several studies have shown 
that the total nitrogen content is decreased in dystrophic 
muscle (Srivastava, 1968; Berilinguet and Srivastava, 1966; 
Srivastava and Berilinguet, 1964). Also, the rate of increase 
in body weight or in leg musculature of the dystrophic mouse
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is only about 50% of normal at 4-8 weeks of age (Gopalan et 
al., 1986a). However, it has been shown that non-collagen 
nitrogen per gram of muscle is not altered (Nihei and 
Filipenko, 1974; Fowler et al., 1977). Since the amount of 
DNA (per unit weight) in muscle is increased, it may be 
concluded that the relative reduction in proteins is due 
either to a decrease in protein synthesis or to an increase in 
protein degradation. Several studies designed to measure the 
rate of protein synthesis in normal and dystrophic muscle have 
shown that the rate of protein synthesis in intact dystrophic 
skeletal muscle is elevated markedly. In dystrophic hamsters, 
the rate of total protein synthesis in_yiyo is nearly two-fold 
greater than in corresponding controls, and the same is true 
for myosin synthesis (Strickland et al., 1979). In 
dystrophic mice (129/ReJ) Garber et al.(1980a) observed that 
the rate of protein synthesis is nearly 5-fold greater than 
litter mate controls. When the identity of the protein 
synthesized was studied using SDS-PAGE they observed that the 
majority of the proteins migrating between heavy chain myosin 
and actin were synthesized in similar proportion in both 
normal and dystrophic muscle. Several differences in the 
relative rates of protein synthesis were observed in lower 
molecular weight proteins such as myosin light chains 1, 2 and 
3 and troponin I and C which all showed a reduced rate of 
synthesis relative to act in and myosin, but still higher than 
in the controls. Using human muscle from Duchenne muscular 
dystrophy patients, lonascescu et al.(1971) observed that
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protein synthesis in_yi.trg is 5—6 times higher than normal 
controls. Their later work showing an increase in number of 
membrane bound ribosomes in preparations from human dystrophic 
muscle also support this view (lonasescu et al., 1981b). 
However, a previous observation, contrary to these, had been 
made where no difference in the ribosomal content of normal 
and dystrophic muscle was noticed (Watts and Reid, 1969). 
According to these workers the "machinery" for protein 
synthesis appears to be normal, and any difference must be due 
to altered concentrations that result from changes in muscle 
volume. Yoshikawa et al. (1984) and Saleem and Nicholls
(1979) observed an increase in the number of EF-2 molecules 
in the cytoplasm of dystrophic muscle which may account for 
the increase in protein synthesis activity observed in 
dystrophic chickens and hamsters. Other studies indicate a 
defective protein synthesis "apparatus". Nicholls et al.(1986) 
have shown that the ability to translate mRNA for tropomyosin 
in the dystrophic hamster muscle homogenate is decreased 
compared with the normal control. Srivastava (1969) showed 
that in dystrophic muscle, incorporâtion of radioactivity into 
low—molecular weight proteins like tropomyosin is higher, 
while that into high molecular weight proteins like myosin is 
lower than normal. Synthesis of actin was not affected.
These findings suggest that the polyribosomal fraction from 
dystrophic muscle is less active, while the monoribosomal 
fraction is more active. Several laboratories have studied
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the synthesis of myosin in dystrophic muscle (Nihei and 
Filipenko, 1974; John et al., 1973; Monckton and Marusyk,
1975). Monckton and Marusyk (1975) used autoradiography and 
showed decreased myofibrillar synthesis ln_ylyg in dystrophic 
muscle of humans. Nihei and Filipenko (1974) also noted a 
decreased in_yiyg synthesis of myosin in murine dystrophy. 
These workers demonstrated that polyribosomes from dystrophic 
muscle are more active in the synthesis of non—myosin 
proteins. A potassium chloride extract from normal 
polyribosomes was found to restore the myosin synthesis 
activity of dystrophic polyribosomes (Nihei and Filipenko, 
1974). Thus, there is considerable evidence to suggest that 
the polyribosomal system from dystrophic muscle is deficient 
in a myosin specific factor(s) and thus may be responsible for 
the impaired synthesis of myosin.
In the past two decades several studies have focused on 
carbohydrate metabolism in dystrophic muscle to determine 
whether alterations in carbohydrate metabolism are the cause 
of muscle weakening in Duchenne muscular dystrophy patients 
(Strickland et al., 1979; Ellis, 1980). The published 
literature on this topic has revealed that several aspects of 
the glycolytic process are altered in dystrophic muscle.
First, mammalian muscle has a reduced capacity for both the 
synthesis and utilization of glycogen. This lesion appears to 
be due to a marked reduction in glycogen, UDP—g1y cosy1 
transferease and glycogen phosphorylase activities (Garber et 
al., 1980a; Dreyfus, 1954 ; Ellis, 1980). Most other
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glycolytic enzymes show some reduction in activity in 
dystrophic muscle. As a result, dystrophic muscle has a 
reduced capacity to produce lactate and ATP (Dreyfus,1954). 
Also, the dystrophic muscle is capable of increased 
utilization of glucose via hexose monophosphate shunt, 
increased synthesis of NADPH and thus an increased synthesis 
of lipids in dystrophic muscle has been proposed by Ellis
(1980). Garber and co-workers have also shown that dystophic 
muscle has a reduced responsiveness to insulin stimulation of 
glucose uptake and adeny1 cyclase activation of epinephrine 
(1980b). However, since adeny1 cyclase from dystrophic muscle 
membrane can be fully activated by sodium fluoride, these 
workers have suggested that the defect in the adeny1 cyclase 
mechanism may be due to a defect in the adrenergic membrane 
receptor or receptor coupling to adeny1 cyclase. In addition 
to this, increased amino acid release especially alanine and 
glutamine was observed by Garber et al. (1978). Amino acid 
formation and release seems to be modulated by the cyclic 
nucleotides in association with insulin and also with other 
agonists. Catecholamines acting through a B-adrenergic 
receptor and in association with increased intracellular 
levels of cAMP are potent inhibitors of alanine and glutamine 
formation and release in skeletal muscle (Garber et al., 1976; 
Garber, 1978). Serotonin (5-hydroxytryptamine) acting 
through D—serotonergic receptors and in association with 
increased levels of cAMP, inhibits alanine and glutamine 
formation and release from muscle (Garber, 1978). The
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increase in amino acid release appears to result, in part, 
from an increase in skeletal muscle protein degradation 
(Garber et al., 1980a). Increased cyclic GMP levels were found 
in dystrophic muscles as compared with normal muscle by the 
same workers, and these higher levels may lead to increased 
rates of muscle proteolysis and hence greater alanine and 
glutamine formation and release. The apparent inability of 
cAMP to inhibit amino acid output may be derived from the 
augmented cGMP level in dystrophic mouse muscle since 
antagonistic roles have been proposed for these cyclic 
nucleotides in other biological systems (Goldberg et al.,
1973).
A symptom of muscular dystrophy of particular clinical 
relevance is the high level of activity of serum creatine 
kinase (Bradley and Fell, 1980). The dramatic elevation of 
serum creatine kinase activity is a diagnostic feature of 
muscular dystrophy in humans, and an increase, though less 
dramatic, occurs in each of the three main animal models of 
the disease. While the increase in serum creatine kinase 
activity is generally assumed to be due to leakage from 
diseased muscle fibres, it is by no means clear what sort or 
extent of cellular damage would be consistent with the 
increased serum activity. Kuby et al.(1977) made a 
remarkable observation regarding creatine kinase. They showed 
by direct isolation of creatine kinase that 3 isoenzymes of 
creatine kinase are present in the musculature of males 
affected by terminal Duchenne muscular dystrophy, whereas only
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the muscle type was to be found in the skeletal muscle of 
normal adult human males. In human brain tissue of both the 
normal and dystrophic animals, only a single isoenzyme could 
be detected and isolated. The creatine kinase isoenzymes from 
dystrophic muscle were compared electrophoretically and 
immunologically with isoenzyme preparations from normal muscle 
(Keutel et al., 1972) and identified as muscle type, hybrid 
type, and brain type. The unique isoenzyme distribution of 
the creatine kinases found in the atrophying muscle of 
patients with Duchenne muscular dystrophy resembles that of 
foetal muscle and this has led to the speculation that the 
major biochemical defect in Duchenne muscular dystrophy may 
lie in the inability to "switch off" the synthesis of 
foetal-like proteins (Schapira, 1967; Schapira et al., 1968; 
Eppenberger et al., 1964; Cao et al., 1968; Dawson et al., 
1968, Kuby et al.(1977) This, in turn, might lead to a 
foetal—like complement of proteins in skeletal muscles, in the 
membrane of muscle, or even within the membrane of red cells. 
Thus , the so-called "leaky" or "fluid" membrane abnormalities 
described for the dystrophic red cell (Butterfield, 1977) 
might simply be another manifestation of a more generalised 
phenomenon, namely that of a foetal—type membrane composed of 
a foetal—like complement of proteins. Other proteins which 
show immature isoenzyme patterns are lactate dehydrogenase 
(Kaplan and Cahn, 1962; Emery, 1964; Tsvetanova and Ognianov, 
1967), myosin (Obinata et al., 1980; Fitzsimons and Hoh, 1981) 
and tropomyosin (Takeda and Nonumura, 1980) in dystrophic
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muscle. The presence of foetal myosin in patients with 
Duchenne muscular dystrophy probably reflects a certain amount 
of muscle régénérât ion, and immaturity of some muscle cells. 
If the suggestion given by Kuby et al.(1977) bears merit, 
the X-1inked Duchenne muscular dystrophy might be an inborn 
error in the final development of the muscle tissue in the 
human male organism such that there is a reversion back to 
foetal development, or that there is a reversion back to the 
foetal state in muscle prior to death.
Many other factors also seem to be impaired in 
dystrophy. Poly-ADPR synthetase decreases during normal 
differentiation of muscle cell (Caplan et al., 1979). A 
delayed decrease in the amount of poly—ADPR in dystrophic 
chickens suggests an abnormal developmental program (Yoshikawa 
and Masaki, 1985). Abnormal acetylcholine esterase content 
has been observed in dystrophic muscle. High levels of 
acetylcholine esterase are found throughout the fibre of 
normal and dystrophic embryo muscles. This activity is 
associated with several molecular forms separable on 
polyacrylamide gels. In the normal muscle, the enzyme levels 
decline after hatching, cytochemical staining decreases and 
low molecular weight forms of this enzyme can no longer be 
detected on polyacrylamide gels. However, in muscles 
afflicted with dystrophy the embryo-1 ike forms are retained. 
Moreover, acetylcholine esterase levels are high, low 
molecular weight forms are present, (seen in polyacrylamide 
gels) and the acetylcholine staining is high in sarcoplasm
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outside motor end—plate regions (Wilson et al., 1970; Linkhart 
and Wilson, 1975 and Wei doff and Wilson, 1977). These 
observations support the idea that there is an error in in 
development and it involves processes mediated by nerve muscle 
interactions.
J . Integrity_of_Biasma_membrane_in_dystrOEhiç_anima1s
The hypothesis that muscular dystrophy is primarily the 
result of a membrane defect has been supported by several 
observations among which are differences in ionic permeability 
of the sarcolemma, decrease in nucleotide and creatine 
phosphate levels, increase in serum levels of several 
intracellular enzymes, and alterations in the plasma membrane 
structures of several cell types.
One of the most striking features of Duchenne muscular 
dystrophy in humans (as indicated earlier) and a commonly used 
clinical indicator of the disease, is an elevation of serum 
creatine kinase which may reach as high as fifty times the 
normal plasma level in the early stages of the disease 
(Munstat et al., 1973 ; Rowland, 1980). The source of this 
enzyme is thought to be due to "leaky" skeletal muscle cells 
which are rich in creatine kinase. However, there is still 
controversy in the literature concerning the relevance of 
creatine kinase as an indicator of Duchenne muscular dystrophy 
since dystrophic human muscle cells in culture do not appear 
to leak creatine kinase into the medium although the 
concentration of creatine kinase is low in these cells. Also,
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
2 ?
the serum level of creatine kinase is not elevated in the 
commonly used strain (129/ReJ) of dystrophic mice (lonasescu 
et al., 1981a; Lieberman et al., 1981). Despite apparent 
strain differences, muscle appears to be the source of plasma 
creatine kinase as uiell as serum aldolase in Duchenne muscular 
dystrophy patients (Strickland et al., 1979; lonasescu et al., 
1981a).
Other evidence which is consistent with the view that 
dystrophic cells are "leaky" comes from measurements of the 
electrolyte content of normal and dystrophic muscle cells. It 
has been shown that dystrophic muscle cells have an elevated 
concentration of sodium and chloride ions and a decreased 
concentration of potassium ions (Strickland et al., 1979; 
Duncan, 1978). However, since the literature contains 
conflicting reports on the integrity of plasma membrane ATPase 
activity in dystrophic tissues, it is still not clear 
whether the alterations in sodium and potassium levels in 
diseased muscle are due to defective Na^/K^ ATPase 
molecules in the plasma membrane or to enhanced "leakyness" 
of the membrane. The change in electrolyte distribution during 
the onset of dystrophy may also be due to the appearance of 
"holes" in the plasma membrane (Cullen and Mastaglia, 1980). 
Regardless of the cause of this defect, the possibility that 
an increase in intracellular calcium in dystrophic muscle 
promotes the activity of muscle proteases capable of degrading 
the myofibrillar proteins has been clearly noted (Kar and 
Pearson, 1976).
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Another membrane defect which has been shown to occur in 
both erythrocytes and muscle of dystrophic humans and mice is 
depletion of transmembrane particles. Freeze fracture 
techniques have revealed that the plasma membrane of both 
erythrocyte and myotubes have 40—60% fewer transmembrane 
particles than normal cells (Cullen and Mastaglia, 1980; 
Munstat et al., 1973; Shivers and Atkinson, 1979). Since these 
membrane particles are involved in transport mechanism, the 
disappearance of these membrane particles in dystrophy 
implicates proteases in the removal of these particles and in 
disruption of transport phenomenon.
K• Iyrngyer_gf_Brgteins_in_dystrgghic_animals
The intracellular process which regulates the mechanism 
of protein turnover is a fundamental problem about which very 
little is known (Katanuma et al., 1976). In skeletal muscle 
the half-life of the proteins in the various muscles of adult 
organism varies from 4—40 days depending on the source of the 
muscle. However, the turnover rate of the various proteins 
is dependent on a number of factors including age, 
nutritional state, hormone balance and level of contractile 
activity of the animal/musele under study (MilIward, 1980). 
Unfortunately, numerous technical problems arise when one 
attempts to measure protein turnover in skeletal muscle (and 
other tissues) which make data assessment extremely difficult 
(Everett and Zak, 1980). Notwithstanding these difficulties.
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it appears certain that protein turnover in dystrophic muscle 
of humans, mice, hamsters, chickens, and cultured dystrophic 
cells is enhanced markedly compared with non-dystrophic 
controls (Young and Munro, 1980; Garber et al., 1980b; Li, 
1980; Ettienne et al., 1980). Moreover, since the outcome of 
dystrophy is muscle wasting, there must be an accelerated rate 
of protein degradation over protein synthesis in_yiyo.
The onset and progression of muscular dystrophy in humans 
and animals is characterized by a marked increase in 
intracellular protease activity in skeletal muscle, leading to 
degradation of myofibrillar proteins, and muscle necrosis.
The proteases showing the greatest increase in activity in 
dystrophic muscle are the thiol proteases, particularly 
cathepsin B (Kar and Pearson, 1977). Goldspink et al.(1977) 
and Rouke (1975) have indicated increased proteolysis in 
muscles in conditions such as muscular dystrophy and the 
important role of lysosomal proteases in degradation of 
myofibrilIs has been suggested by Weinstock and lodice 
(1969). Since increased lysosomal enzyme activities are found 
in experimental myopathies and hereditary muscular dystrophy, 
these enzymes are frequently implicated as a major factor in 
the muscle wasting process. Consistent with this idea, 
increased levels of cathepsin B have been observed in muscle 
of patients with muscular dystrophy and related diseases (Kar 
and Pearson, 1977; Katanuma et al., 1977). Also, lysosomal 
(thiol) proteases such as cathepsins B and L were found to 
degrade purified myofibrillar proteins in_yi.trg though in
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different ways (Schwartz and Bird, 1977; Noda et al., 1980; 
Matsukura et al., 1981). Given that the thiol proteases have 
been shown to degrade a wide variety of sarcoplasmic and 
myofibrillar proteins in_yi.tro, it would appear that control 
of these enzymes in vivo is of vital importance in maintaining 
normal cell function.
In recent years considerable attention has focused on the 
physiological role of protease inhibitors in the process of 
protein metabolism (Lasowski et al., 1980). Since the time 
Frankenstadt (1957) first reported the presence of endogenous 
thiol protease inhibitors in rat liver, many workers have 
attempted to purify and characterize these inhibitors. The 
inhibition of proteases by protein inhibitors is an intriguing 
problem in studies of specific protein—protein interactions 
(Ruhlman et al., 1973; Mitsui et al., 1979). It has been 
reported that several cathepsins of lysosomal origin which 
play an important role in regulating the degradation of 
soluble and structural proteins in many tissues have specific 
endogenous inhibitors (Lenney, 1980). Several thiol
proteinase inhibitors have been isolated from mammalian 
tissues (Udaka et al., 1965; Jarvinen, 1976; Lenney et al., 
1979; Kopitar et al., 1978; Hibino et al., 1980; Kominami et 
al., 1982) which form reversible complexes either with a 
specific protease or its substrate. Those which affect metal 
containing proteases are usually larger proteins. In most 
tissues, these inhibitors are localised in the cytosol 
fraction of the cell, whereas the majority of the proteases
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are associated with organe1 les such as lysosomes, golgi or in 
other particulate fractions (Lenney, 1980). Furthermore, 
three low molecular weight thiol protease inhibitors were 
detected in human epidermis (Jarvinen, 1978). Hibino et al.
(1980) indicated that a protease inhibitor purified from new 
born rat epidermis was synthesized in epidermal cells during 
keratinization. Ohitani et al. (1982) showed only subtle 
differences in inhibitory activity between inhibitor from new 
born rat and human epidermis towards several thiol proteases 
despite significant differences in sequence homology.
Of relevance is the finding of Schwartz and Bird (1977) 
who reported that rat muscle contains 2 inhibitors of 
cathepsin B activity which can be inactivated by incubation of 
muscle extracts at pH 4.5. These inhibitors have not been 
fully character ised but they have molecular weights of 12,500 
and 62,000 dal tons. It is presumed that the activity of 
cathepsin B in muscle is regulated by these endogenous 
inhibitors which are, in turn, regulated by hydrolases or some 
other mechanism (Schwartz and Bird, 1977). The importance of 
proteinase inhibitors which suppress the activity of cathepsin 
B and D and calcium activated neutral protease in normal 
muscle, and which may be lost in diseased muscle, has been 
suggested by the studies of Libby and Goldberg (1978) and 
Stracher et al. (1978). In this respect, the findings of 
Spanier and Bird (1982) are most interesting. They have shown 
that the gastronemius and masseter muscles from female guinea 
pigs maintained on a vitamin E deficient diet have reduced
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cathepsin B inhibitor activity compared to similar cytosol 
fractions prepared from guinea pigs on a normal diet. 
Furthermore, they suggested that the apparent increase in 
cathepsin B activity in muscle extract of vitamin E deficient 
animals, and perhaps in dystrophic muscles, may be 
attributable to a decreased level of endogenous protease 
inhibitor in these groups of animals. Of considerable 
significance to the above findings are the results of Stracher 
et al. (1978) who showed that leupeptin, an effective 
inhibitor of cathepsin B and calcium activated neutral 
protease, and pepstatin, an inhibitor of cathepsin D, inhibit 
both the rate of total protein degradation and cathepsin B 
activity in intact rat muscle in_yitrg. Moreover, Libby and 
Goldberg (1978) have reported that leupeptin and pepstatin are 
able to offer some protection to the general architecture of 
chick muscle and to reduce markedly the high level of serum 
creatine kinase in dystrophic chicken when injections are 
started one day after hatching. In other studies, Sher et al.
(1981) have reported that leupept in treatment (via I.P. 
injections) of 3 week old mice with genetic muscular dystrophy 
delays the appearance of myopathy for at least 24 weeks. 
Recently, Tsuji and Matsushita (1986) have reported successful 
control of depeptidy1 peptidase activity in dystrophic mice 
with the protease inhibitor bestatin along with the 
disappearance of myopathological features characteristic of 
the disease. These studies, while incomplete, strongly 
suggest that the loss of control of protease activity in
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skeletal muscle is of fundamental importance in the onset and 
development of muscle wasting characteristic of various muscle 
diseases. While a potential role for protease inhibitors as 
modulators of intracellular proteolysis has been recognised, 
the intracellular function of the molecules involved are not 
very well understood. Since, the tissue proteins are subject 
to continuous turnover, a control mechanism must exist to 
ensure protein homeostasis and this control could also be 
performed by protease inhibitors. Thiol protease inhibitors 
assayed for activity against cathepsin H have been found in 
all organs of the rat (Kominami et al., 1982b).
Immunodiffusion analysis with anti-liver thiol protease 
inhibitor serum indicated that the inhibitor in rat liver is 
immunologically identical with the inhibitor in other rat 
tissues (Kominami et al., 1982b). However, contrary results 
have been reported recently where anti—rat liver inhibitor 
serum did not react with anti-rat epidermis serum (Katanuma 
and Kominami, 1983). A comparison of the properties of the 
purified inhibitors showed that at least two different types 
of thiol proteinase inhibitors are present in the cell, the 
liver type and the epidermal type. The presence of inhibitors 
in various other tissues of mammals, including pigs, hamsters, 
rabbits, and humans has been reported (Lenney et al., 1979; 
Turk et al., 1982). Thus intracellular protease inhibitors 
seem to be ubiquitous in mammals. However, species 
specificity exists since, anti—rat protease inhibitor serum 
did not cross react with either human or rabbit protease
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inhibitor (Wakamatsu et al., 1982).
Since the wasting of muscles in the various forms of 
muscular dystrophy is obviously the consequence of breakdown 
occuring at a rate exceeding that of resynthesis, a natural 
approach to control this situation is to try and inhibit the 
proteases responsible for the excessive degradation. The 
finding that muscle tissue extracts contain inhibitory 
activity against thiol proteases (Schwartz and Bird, 1977) 
prompted us to examine whether these inhibitors might be 
involved in the modulation of protease activity in normal 
muscle and whether changes, if any, in inhibitor activity 
occur in dystrophic muscle which might be the cause for the 
increased protease activity found in the diseased muscle.
This dissertation describes the purification and properties of 
a thiol protease inhibitor from normal and dystrophic hindlimb 
muscle of the mouse of strain 129/ReJ. This study, a part of 
which has been published (Gopalan et al., 1986b) also shows 
that the thiol protease inhibitor from dystrophic muscle is 
functionally defective in the control of cathepsin B activity 
compared with the thiol protease inhibitor protein from normal 
mouse 1i ttermates.
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II. MATERIALS AND METHODS
A. Animals
Dystrophic male mice (strain 129/ReJ-dy) and their normal 
1ittermates were obtained from Jackson Laboratories (Bar 
Harbor, Maine) at about 30 days of age and maintained in the 
laboratory to age 60 days on standard laboratory chow 
(Purina). Also, female mice of strain 129/ReJ, heterozygous 
for the disease and normal retired breeders of the same strain 
of about 9 months of age were used.
B. Bigchemicals
N- (/- ben zoy1-DL-arg ini ne-2-naph t hy1am i de (BANA),
N-oT-CBZ-L-arg iny1-L-arg inine-4-methoxy-B-naphthy1amide. Fast 
Garnet GBC salt, azocaesin, rabbit myosin and pi markers for 
isoelectric focusing were purchased from Sigma Chemical Co 
(St Louis, Mo.). The protein molecular weight markers for 
electrophoresis were from Pharmacia (Montreal, P. Q.). The 
Chemopack C-18 HPLC column was prepared by Dr. F. L. Huang 
from material obtained from Chemco Scientific Co. (Osaka, 
Japan). Acetonitrile was of HPLC grade and the pi 3.5-10 
ampholytes were from LKB (Fisher Scientific, Toronto, Ont.). 
Ultrafi1tration Diaflo membranes were from Ami con Corp. 
(Danvers, Ma.). Aery1amide and SDS were from BioRad 
Laboratories (Mississuaga, Ont.). All other chemicals were of 
reagent grade or better.
35
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c. Methods
1• Iissue_samEie_BreBaration
The tissues for isolation of thiol proteases and thiol 
protease inhibitors (TPI’s) were obtained by cervical 
dislocation of the animals and the tissues perfused in_situ by 
pumping 40 ml of mammalian Ringers solution containing □.1 mM 
EDTA through the animal at 20 ml per minute using direct 
cardiac puncture. The total hindlimb muscle and liver were 
excised and used either immediately or stored at —70 C.
2. Preparation_of_mouse_1iver_1ysgsoma1_thig1_grgteases
Frozen livers from normal and dystrophic 60 day old male 
mice were thawed, cut into small pieces and ground with fine 
glass beads and 5 volumes of ice-cold 0.25 M sucrose in a 
mortar and pestle at 4 C. The homogenate was centrifuged at 
600 X g for 10 minutes to remove intact cells and nuclei. The 
resulting supernatant was centrifuged at 27,000 x g for 20 
minutes to pellet the mitochondria and lysosomes (M+L). The 
crude M+L pellet was washed with about 25 volumes of 0.25 M 
sucrose solution containing 0.1 mM EDTA and 0.03 M Tris-HCl, 
pH 7.0, and the M+L fraction was collected again by 
centrifugation as above. The resulting M+L pellet was 
suspended in 20mM sodium acetate, pH 5, containing 1 mM 
dithiothreitoi (DTT), 0.1 mM EDTA and 10% glycerol and 
homogenized thoroughly in a ground glass homogenizer. The 
homogenate was centrifuged at 27,000 x g and the resulting 
pel let re-homogenized 3-4 times. The 27,000 x g supernatant
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fractions were pooled and concentrated by ultrafi1tration on a 
Diaflo YM-3 membrane and used as the source of lysosomal 
(total) thiol proteases.
3. Partial_Burifiçatign_gf_çatheBsins_B^_H_and_L_frgm_mguse
liver_lysgsgmes
Cathepsins B (EC 3.4.22.1), H (EC 3.4.22.16) and L (EC 
3.4.22.15) were prepared from the crude lysosomal extract from 
mouse liver according to the procedure of Barrett and Kirschke
(1981) with slight modifications. The total M + L  extract was 
concentrated to about 2 ml by ultrafiltration as described 
above and passed through a Sephadex G—75 column (1 x 50cm) 
equilibrated with 20 mM sodium phosphate buffer pH 6, 
containing 1 mM DTT and 0.1 mM EDTA and 10% glycerol. The 
fractions giving a positive reaction to N— benzoy1—DL— 
arginine—2—naphthylamide (BANA) as substrate were pooled and 
concentrated on a Diaflo YM—5 membrane. The enzyme 
concentrate was applied to a DEAE—cellulose column (DE—32, 1
X 19 cm) equilibrated with 20 mM sodium phosphate, pH 6, 
containing 1 mM DTT, 0.1 mM EDTA, and 10% glycerol. The 
column was washed with the equilibrating buffer and cathepsin 
H (which does not bind to DEAE-cellulose) was collected in the 
wash and concentrated by ultrafiltration (YM—5). Cathepsins B 
and L were eluted from the column by stepwise elution with 0.2 
M and 0.45 M NaCl, respectively, in the equilibrating buffer. 
Each protease fraction collected from the column was pooled 
and concentrated by ultrafiltration using a YM-3 filter.
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Cathepsins B, H and L prepared as above were used as test 
thiol proteases in the inhibitor assays.
4. Assay_fgr_cathegsins_B_and_H
The assay conditions for cathepsin B and H were the same 
except that BANA was used as substrate for cathepsin H and 
N— CBZ— L—arg iny1—L—arg in ine—4—methoxy—naphthy1ami de was used
as the susbstrate for cathepsin B. The reaction mixture 
contained 0.05 ml of enzyme, 0.05 ml of incubation buffer 
containing 0.074 M potassium phosphate, 1 mM EDTA and O.024% 
cysteine (freshly prepared), and 0.05 ml of water. The 
reaction mix was incubated at 40 C for 5 min and then 0.010 ml 
of BANA (40 mg/ml) or N-X“CBZ-L-arginyl-arginine-4-methoxy- 
naphthy lami de (10 mg/ml) was added to start the reaction.
After O, 15, and 30 minutes, 0.05 ml of the reaction mixture 
was removed into 0.025 ml of coupling reagent (pH 6.0) 
containing 0.36% ch1oromercuribenzoate (PCMB) and 1.86% EDTA 
in 0.05M NaOH, and kept on ice. Color development occurred 
upon addition of 0.025 ml of a fast garnet salt solution 
(0.005% fast garnet in 4% BriJ 35). Butanol was added to 
extract the colored complex and the samples were centrifuged 
in a clinical centrifuge to separate the phases. The organic 
phase was removed and analyzed at 520 nm. One enzyme unit of 
cathepsin B or H is defined as the liberation of 1 nmole of 
naphthylamine per hour in a standard enzyme reaction mix.
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3. Assau for cathepsin L
Azocaesin was used as substrate to determine the TPl 
activity on cathepsin L according to the procedure of Barrett 
and Kirschke (1981). Azocaesin is a derivative of caesin in 
which the tyrosine and histidine side chains have been coupled 
with diazotized sulfani1ic acid or sulfanilamide in alkali.
The azo—coupling confers an intense yellow color on the 
protein. Proteolytic degradation of azocaesin yields peptides 
soluble in dilute TCA solution, which may be quantified by 
their absorbance at 366 nm. The method is especially suited 
for the determination of proteolytic activity in crude 
samples, being very résistent to interference. The assay for 
cathepsin L is made very specific by the inclusion of 3M urea 
which enhances the activity of cathepsin L and depresses that 
of cathepsin B. Thus for the cathepsin L assay, 0.25 ml of 
enzyme preparation was mixed with O.25 ml of an assay buffer 
containing 0.1 M sodium acetate, pH 5, and 1 mti EDTA and 40 mM 
cysteine (freshly prepared). After 5 minutes at room 
temperature, 0.3 ml of an azocaesin-urea mixture (10 ml of 6% 
azocaesin and 10.8 g of urea in a final volume of 30 ml assay 
buffer lacking cysteine) was added. After O, 15, and 30 
minutes, 1 ml of 3% TCA was added to the reaction vessels and 
the mixture centrifuged in a clinical centrifuge. The 
supernatant was removed and analyzed at 366 nm. One enzyme 
unit of cathepsin L is defined as the amount of enzyme which 
brings about a change of 0.01 A^66 minute.
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6 - Assay s_gf _ t h i g l^gr g t easg_ i niî i b i t or _aç t i y i ty
Determination of thiol protease inhibitor (TPI) activity 
during the purification procedure was carried out using the 
crude M+L extract as described above as the source of the 
total lysosomal thiol proteases. N— — benzoyl—DL—arginine — 
2—naphthylamide (BANA) was used as the substrate. The extent 
of 2—naphthylamine liberation from BANA by thiol proteases, in 
the presence of various column fractions (see purification of 
inhibitor in Results), was measured using the procedure of 
Barrett (1972). Each reaction vessel contained 0.075 M 
potassium phosphate, pH 6, 1 mM EDTA, O.024% cysteine, 1 mg/ml 
BANA, 40-50 milliunits of thiol protease activity, and 0.1 ml 
of various column fractions in 0.8 ml total volume. Aliquots 
of 0.25 ml were removed after an appropriate incubation period 
at 40 C (usually 30 minutes), and the percent inhibition of 
2-naphthylamine liberation was determined.
The inhibitor activity in each TPI preparation was 
measured using papain (EC 3.4.4.10) and cathepsins B, H and L 
as test proteases. With papain or cathepsins B as the test 
protease, the substrate was N— JL— CBZ-L-arg i ny1—arg ini ne— 
4-methoxy-naphthylamide while with cathepsin H the substrate 
was BANA. Azocaesin was the substrate for cathepsin L. One 
inhibitor unit is defined as the amount of protein required to 
reduce the thiol protease activity by one enzyme unit.
7. Purity_and_mglecular_weight_determinatigns_gf_the_TPlls
The purity and molecular weight of the TPI from normal and
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dystrophic mouse muscle were analyzed on 7 18% gradients of 
polyaery1ami de gels (1.5 x 100 x 135 mm) containing 0.1% 
sodium dodecyl sulfate (SDS) according to the procedure of 
Laemmli (1970). Protein was stained with Coomassie brilliant 
blue (R-250) in 7.5% acetic acid and 50% methanol, and the gel 
destained in a solution composed of 7.5% acetic acid and 5% 
methanol. The molecular weight of the TPI’s was determined 
using the following standard molecular weight markers: 
phosphorylase b (Mr 94,000), bovine serum albumin (Mr 67,000), 
ovalbumin (Mr 43,000), carbonic anhydrase (Mr 30,000), soybean 
trypsin inhibitor (Mr 20,100) and /-lactalbumin (Mr 14,400).
8. Analysis_gf_IPIls_gn_isoeleçtriç_foçusing_gels
Isoelectric focusing of the purified TPI’s was carried out 
in Jacketed glass columns (4 x 100 mm) containing 6% 
polyacrylamide gels with 2% of 3.5—10 ampholytes according to
the procedure of Blerkom (1970). Electrophoresis was carried
out for at least 6 hours at 75 volts and 0.5 ma per column. At 
the end of the run, one gel from each set was cut into 2 mm 
sections, and each section was placed in a vial containing 1.2 
ml of nanopure water. The vials were covered with parafilm and 
after three to four hours at room temperature, the pH of each 
gel extract was measured using a micro-pH electrode. A second 
gel was washed in ice-cold water overnight with at least 4 
changes of fresh cold water, and then cut into 2 mm sections,
and each section was placed in a vial containing 0.5 ml of 50
mM Tris-HCl and 0.2 M NaCl, pH 8. After incubation at 40 C
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for 30 minutes, the amount of thiol protease inhibitor in each 
gel extract was determined using either papain or cathepsin B 
as test protease as described above. A third gel was placed 
in 5% TCA for 3 hours and subsequently stained for protein 
with Coomassie blue as described above for the
SDS—polyacrylamide gels. In some experiments standard proteins 
with known pi values were run along with the TPI’s to provide 
an additional means of assessing the pi values of the TPI’s. 
The standard protein mix for the latter assay contained 
amyloglucosidase (pi 3.53), methyl red (pi 3.73), soybean 
trypsin inhibitor (pi 4.55), p-lactoglobulin A (pi 5.13), 
carbonic anhydrase (pi 5.85), myoglobin (pi 7.16 and 6.76), 
and L-lactic dehydrogenase (pi 8.55).
9• High_Berfgrmançe_liguid_çhrgmatggraghy_gf_TPIls
Thiol protease inhibitor from normal and dystrophic muscle 
was analyzed on a C-18 reverse phase column (4.6 x 250 mm, 
Chemopack) driven by a Gilson HPLC system. The column was 
equilibrated with 12% acetonitrile containing G.1% 
trifluoroacetic acid (TFA), and following sample injection, 
the protein was eluted at a flow rate of 1 ml/min using a 
linear gradient (40 minutes) of acetonitrile to 60% with 0.1% 
TFA. The column effluent was monitored at 214 nm using a 
Gilson Holochrome detector.
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10. Assay_fgr_mygsin_bUdrglysis_by_çatheBsin_B_in_the_
gresence_gf_TPl3Q_and_TPIzd
The effect of TPI-n and TPI-d on the hydrolysis of rabbit 
myosin was analyzed on a 7-18% SDS-polyacrylamide gel as 
described above. Reaction vessels containing 20 mM sodium 
acetate pH 5, 1 mM EDTA, 1 mM DTT, 0.15 M KCl, 10 % glycerol, 
rabbit myosin 0 8  >ig), cathepsin B (16.8 mi 11 i-units) , and 
TPI-n (46 >ig) or TPI-d (46 >ig) in separate reaction vessels 
were incubated at 40 C for periods up to 1 hour. The 
reactions were stopped at the desired time by heating an 
aliquot of the reaction mixture at 95 C for 5 minutes in the 
presence of 1 % SDS. Samples were then applied to an 
SDS—polyacrylamide gel slab and electrophoresed at 130 volts 
for 3 hours.
11. Thymgl_sulfuric_açid_test_fgr_glyçggrgteins
The presence of glycoprotein in the TPI-n and TPI—d 
preparations was tested using the thymol—sulpfuric acid method 
outlined by Gander (1984). After electrophoresis the gels 
were washed with isopropanol—acetic acid-water (25:10:65) for 
at least 2 hours to fix the proteins and to remove the low 
molecular weight substances. After two additional washes the 
final wash was done for another 2 hours in the same solvent 
containing 0.2% thymol (w/v). After washing with thymol, the 
gel was transferred to a solution of concentrated sulfuric 
acid and absolute ethanol (80:20) and shaken at room 
temperature for a minimum of 2 hours or until the opalascent
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appearance of the gels Just disappeared. Zones containing 
glycoproteins stained red, whereas the background remained 
yellow. Proteins lacking carbohydrate markers do not form red 
bands when treated in this manner.
The normal and dystrophic inhibitor proteins were run on 
a 7—18% SDS—polyacrylamide gel and stained for glycoproteins 
using an acid protease from Artemia embryos, a known 
glycoprotein, as a marker.
12. Protein_determlnation
The protein content of each enzyme and inhibitor 
preparation was determined by the method of Lowry et 
al.(1951) using bovine serum albumin as protein standard.
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III. RESULTS
A. Purificatign_of_a_thiol_BrgteasG_inhibitgr_frgm_ngrmal_and 
dystrgghic_mguse_muscle
The low molecular weight thiol protease inhibitors from 
60 day old normal (TPI—n) and dystrophic (TPI—d) mouse 
hindlimb muscle were purified to apparent homogeneity as 
described by Hirado et al. (1981) with slight modification. 
Approximately 4—5 grams of hindlimb muscle from 3 normal or 6 
dystrophic mice were homogenised thoroughly with 5 volumes of 
10 mM Tris-HCl, pH 8.0 containing 1 mM dithiothreitoi, 0.2 M 
NaCl and 10% glycerol in a loose fitting ground—glass 
homogenizer. In each case the homogenate was centrifuged at 
27,000 X g for 20 minutes and the supernatant fluid passed 
through miracloth to remove any floating material. The 
filtrate was adjusted to pH 5.0 with acetic acid and then 
stirred for 3-4 hours at 4 C. The precipitate that formed at 
pH 5 was removed by centrifugation and the crude extract was 
concentrated to about 2 ml by ultrafiltration using a Diaflo 
YM—5 (Amicon) membrane.
After concentration, the crude extracts from normal and 
dystrophic muscle were applied (separately) to a Sephadex G—50 
column (1 X 50 cm, superfine) equilibrated with the 
homogenization buffer, and the protein was eluted with the 
same buffer. Each column fraction was assayed for UV 
absorbing material at 280 nm and for TPI activity using a
45
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crude thiol protease preparation front normal mouse liver and 
benzoyl arginine naphthylamide (BANA) as substrate at pH 6.
The column fractions containing inhibitor activity were pooled 
and concentrated by ultrafiltration using a Diaflo YM—2 
(Amicon) membrane.
The concentrated TPI preparation from the Sephadex G-50 
column was applied to a Sephadex G—75 column (1 x 50 cm, 
superfine) equilibrated with homogenization buffer, and the 
protein was eluted and analyzed as described above for the 
first gel filtration step. The column fractions containing 
inhibitor activity were pooled and concentrated by 
ultrafiltration on a Diaflo YC—05 (Amicon) membrane. The TPI 
preparation was rechromatographed on a second Sephadex G—75 
column and fractions containing inhibitor activity were pooled 
and concentrated as before. The final préparâtions, 
designated as TPI-n from normal mouse muscle and TPI-d from 
dystrophic mouse muscle were stored at —20 C.
The results in Figure 2 show the elution and activity 
profiles of the TPI’s after each chromatographic step. The 
protein content and inhibitor activity after each step in the 
purification process are also summarized in Table 1. Two 
aspects of the data in Table 1 are notable. First, it is 
clear that crude extracts of dystrophic muscle contain about 
75% less inhibitor activity than crude extracts from normal 
muscle, data which are consistent with that reported 
previously from this laboratory (Gopalan et al., 1986a).
Since I did not attempt to inactivate the thiol protease
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Figure 2- Purification of TPI-n and TPI-d on gel filtration 
columns. All columns (1 x 50 cm) were 
equilibrated with buffer containing 10 mM Tris-HCl, 
pH By 0.2 M NaCl, 1 mM DTT and 10% glycerol. The 
protein was eluted with the same buffer.
Panel A: Crude extract from hindlimb of normal
mice on Sephadex G—50 (superfine) column 
B: TPI-n activity on the first Sephadex G—75
(superfine) column from pool of Sephadex 
G-r50 column material (A).
C: TPI-n activity on second Sephadex G-75
(superfine) column from pooled material 
from the first Sepahdex G—75 column (B)
D: Crude extract from hindlimb of dystrophic
mice on Sephadex G—50 (superfine) column. 
E: TPI-d activity on the first Sephadex G-75
(superfine column) from pool of Sephadex 
G—50 column (D).
F: TPI-d activity on the second Sephadex
G-75 (superfine) column from pooled 
material from the first Sephadex G-75 
column (E).
O---0, protein as measured by absorbance at A2b o*
X--- X, inhibitor activity (as percent inhibition)
using total lysosomal thiol proteases with 
BANA as substrate.
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Table 1. Summar U_Qf _s t ees_ i.n _ t he_gur if iça t ign _g f _ t h i g l._Br g t ease 
i!ïbibitgr_frgm_ngrmai_and_dystrgghiç_mguse_musçle^
Fract ion^ Total Protein Total
(mg) milli-IU
Specific 
Act ivi ty
Normal muscle"
Crude extract 36.6 760 21
Sephadex G-50 32.3 1160 36
1st
Sephadex G—75 5.6 1388 248
2nd
Sephadex G—75 2.4 1203 501
Dystrophic muscle^
Crude extract 43.8 198 5
Sephadex G—50 20.8 1285 62
1st
Sephadex G-75 3. 7 1012 274
2nd
Sephadex G—75 2.7 891 330
^ Each preparation was assayed using 41 milliunits of thiol 
protease activity in a standard reaction vessel.
*^4.5 grams of muscle were taken from normal mice and 
4.6 grams were taken from dystrophic mice.
The data presented in this Table are représentâtive of one of 15 
experiments conducted.
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activity in the crude extracts, it is likely that the low 
inhibitor levels in these preparations are due to elevated 
amounts of these enzymes which lower the apparent inhibitor 
activity (Ohtani et. al., 1982). Second, the total TPI 
activity in the final preparation (after the 2nd Sephadex G-75 
step) is about 35% higher in preparations from normal muscle 
than from dystrophic muscle. These differences are not 
significant for reasons described below.
In several other preliminary experiments, attempts to 
purify the protease inhibitor on CM—cellulose, DEAE-cellulose, 
CM-affigel blue, agarose blue, papain sepharose, and Con-A 
sepharose columns were made.. In all of these cases 
unsatisfactory yields of activity were obtained (compared with 
the gel filtration protocol used here) so further attempts to 
use these media to purify the inhibitor were abandoned.
B. Physical_BrgBerties_gf_the_thigl_grgtease_inhibitgr_frgm 
DQrmal_and_dystrgBhic_hindlimb_muscle_gf_the_mguse 
Selected physical properties of TPI-n and TPI-d 
Preparations after the second Sephadex G-75 column were 
analyzed using three analytical procedures: SDS-polyacry1-
amide gel electrophoresis, high performance liquid 
chromatography, and analytical isoelectric focusing. The 
migration property of the protein in each TPI preparation on a 
7—18% gradient of polyacrylamide in the presence of O.1% SDS 
is shown in Figure 3. These data show that only one 
polypeptide is present in each inhibitor preparation, and
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Figure 3. Comparison of TPI—n and TPI—d after SDS—polyacryI— 
amide gel electrophoresis. Samples of each thiol 
protease inhibitor preparation, after the second 
Sephadex G—75 step were electrophoresed on a 7—18% 
polyacrylamide gel in the presence of 0.1% SDS. 
Lanes 1 and 4 are standard molecular weight 
proteins. Lane 2 contains 20 jig TPI-n while lane 3 
contains 20 jig TPI-d.
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based on migration distances of the TPI’s compared with 
standard protein markers, the molecular weight of each TPI was 
calculated to be 14,800. The latter results are shown in 
Figure 4. The results in Figure 5 compare the elution 
P>“ofiles of TPI-n and TPI-d from an HPLC column (4.6 x 250 mm, 
Chemopack). The column was eluted with a linear gradient (40 
minutes) of acetonitrile to 60% containing 0.1% TFA. Only one 
major protein peak was detected in each preparation. TPI—n 
and TPI-d also co—eluted from the HPLC column when present as 
s mixture (data not shown). Both TPI—n and TPI-d eluted from 
^he HPLC column at 47% acetonitrile.
Data from the analytical isoelectric focusing experiments 
shown in Figure 6. The only protein detectable on these 
Gels after staining with Coomassie brilliant blue focused at 
pH 4.5. Mixtures of TPI-n and TPI—d also gave a single band 
Upon focusing at pH 4.5. These data show that both TPI-n and 
d are apparently homogeneous after the second Sephadex 
®~75 step and that they have very similar, if not identical, 
physical properties.
^• ÔÇtivitu_gf_IPi-n_and_IPi-d_gn_varigus_thiol_ergteases
The inhibitor activity of purified TPI-n and TPI-d was 
compared using papain and cathepsins B, H and L and the 
'Results are shown in Figure 7. When both TPI’s were tested 
^gainst papain, no differences in inhibitor activity were 
found, and both TPI’s inhibited papain by 50% (ID^g) at 4 
. With normal mouse liver cathepsin B, TPI-d was 
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
54
Figure 4. Molecular weight determination of the thiol
protease inhibitor protein- Standard protein 
markers used were phosphory1ase b (94,000), bovine 
serum albumin (67,000), ovalbumin (43,000), 
carbonic anhydrase (30,000) soybean trypsin 
inhibitor (20,100), and oC-lactalbumin (14,400).
The arrow indicates the electrophoretic position of 
TPI-n on the gel compared to the standard proteins.
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Figure 5. High performance liquid chromatography of TPI—n and 
TPI—d. Samples of TPI-n (10 >ag) and TPI-d (5 ^ g ) 
were applied in separate runs to a C-18 reverse 
phase column (Chemopack, 4.6 x 250 mm) previously 
equilibrated with 12% acetonitrile containing 0.1% 
TFA. The columns were developed with a linear 
gradient (over 40 min duration) of acetonitrile to 
60% containing 0.1% TFA- The actual tracing from 
the recorder is shown here including the column 
pressure curve (p) and zero voltage curve (v). The 
small vertical arrows indicate material present in 
the buffer as observed in a separate run (not 
shown).
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Figure 6. Isoelectric focusing gels containing TPI-n and 
TPI-d and a mixture of TPI-n and TPI-d. The pi 
of the standard proteins are shown at the far 
left.
Lane 1. Standard protein mix together with TPI-n
+TPI-d.
Lane 2. TPI-n only (20 jag).
Lane 3, TPI-d only (20 jag).
Lane 4. TPI-n + TPI-d (40 jag total)-
The standard proteins used were: L—Lactic 
dehydrogenase (pi 8.55), myoglobin (pi 7.16 and 
6.76), carbonic anhydrase (5.75), p—lactoglobulin 
A (pi 5.13), methyl red (3.75) and amyloglucosidase 
(pi 3.55).
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Figure 7, Effect of TPI—n and TPI—d on the activity of 
various thiol proteases. Varying amounts of 
inhibitor from normal (N) and dystrophic (D) muscle 
were added to a standard reaction vessel containing 
one of the thiol proteases indicated, and the 
percent inhibition was determined.
X ---- X, indicates TPI from normal muscle.
8 ----- indicates TPI from dystrophic muscle.
Cathepsins B, H and L were from normal mouse liver»
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inactive while TPI-n had an IDgg of 7.5 jjg/ml. No 
significant differences in inhibitor activity were observed 
using cathepsin L, while with cathepsin H about 35% more TPI—d 
was required to reach the IDgg level. Similar findings were 
observed using cathepsin B, H and L isolated from livers of 
dystrophic mice. These findings are summarized in Table 2. 
Thus while the thiol protease inhibitor from normal mouse 
muscle (TPI—n) appears to be effective in the regulation of 
papain and homologous cathepsins B, H and L, the thiol 
protease inhibitor from dystrophic mouse muscle (TPI-d) 
appears to be inactive against cathepsin B, partially active 
when cathepsin H is used, and fully active when cathepsin L 
and papain are the test enzymes. The fact that TPI—d 
preparations are unable to regulate cathepsin B activity under 
Conditions (in vitro) where TPI—n preparations are active is 
an important observation.
0• ActiVity_of_IPI-n_and_IPI-d_after_isoe1ectric_fOÇUSing_gn 
BQiuacrylamide_gels
To ascertain whether the inhibitor activity in each 
preparation is associated with the major protein observed on 
SDS-po1yaery1amide and isoelectric focusing gels, 10-20 ;jg of 
each TPI preparation were electrophoresed on analytical 
isoelectric focusing gel columns, either separately or as a 
mixture. One gel was left intact and analyzed for protein by 
staining with Coomassie brilliant blue (R—250), while the 
other gels were cut into 2 mm sections. One of the latter was
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used to determine the pH gradient that formed during the 
electrophoretic run. From the other cut gels, protein was 
eluted with 30 mM Tris—MCI containing Ü.2 M NaCl, pH 8. In 
one of these gels, protein from each section was extracted and 
assayed for inhibitor activity against papain, while in the 
other gel, extracts of sections were assayed for inhibitor 
activity against cathepsin B. Results of these experiments 
are shown in Figure 8.
As observed previously (see Figure 6), only one discrete 
protein band could be detected in either TPI—n or TPI—d 
préparât ions. The pH at which this protein focused (pl) was 
determined to be 4.5 by direct pH measurements of individual 
gel sections (as shown in Figure 8), and by the use of protein 
standards with known pi values as shown in Figure 9. Assays 
of protein eluted from the gel sections revealed that while 
the TPI—n of pi 4.5 is active against both papain and 
cathepsin B, the pi 4.5 protein in the TPI—d preparation is 
inactive against both of these proteases. However, the agent 
in the TPI—d preparation which inhibited papain in other 
experiments (see Figure 7) focused at pH 4.9. This inhibitor 
could not be detected with Coomassie blue stain, and it was 
clearly different from the major protein which focused at pH 
4.5, When equal amounts of TPI—n and TPI—d preparations were 
combined, electrophoresed on an analytical isoelectric 
focusing gel column, and then analyzed for inhibitor activity 
as before, both inhibitor activities were detectable using 
papain as the test thiol protease (see Figure 8c). These
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Figure 8. Analysis of TPI—n and TPI—d on analytical
isoelectric focusing gels. Samples containing 
either TPI—n (20 jjg), TPI—d (20 jag) or a mixture of 
both (TPI-n + TPI-d, 40 jag) were run on analytical 
isoelectric focusing gels, then analysed for 
protease activity using either papain (panel A, Bj 
C) or cathepsin B (panel D, E, and F) as test 
proteases. The photograph at the top of each panel 
shows the Coomassie blue stained protein in gels
run in parallel compared to the pH gradient (---)
and inhibitor activity in separate gels containing
TPI-n (X --- x) and TPI-d (1  #) or a mixture
inhibitor proteins.
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Figure 9. Determination of pi values of the thiol protease
inhibitor protein. Standard proteins with known pi 
values were run with normal mouse muscle TPI as 
shown in Figure 6.
Standard proteins used were 1)lactic dehydrogenase 
(pi 8.55), 2 and 2a) myoglobin (pi 7.16 and 6.76), 
3) carbonic anhydrase (pi 5.85), 4) lactoglobulin 
(pi 5.13), 5) methyl red (pi 3.75), and 
6) amyloglucosidase (pi 3.55). The arrow 
indicates the position of the inhibitor protein in 
the gel.
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results demonstrate that the TPI—d protein which focuses at pH 
4.5 lacks inhibitor activity using either papain or cathepsin 
B as the test protease. Otherwise it is identical to TPI-n 
which is active on papain and cathepsin B. The inhibitory 
activity in the TPI-d preparations must be due to some other 
substance, either a protein in amounts too small to be 
detected by staining with Coomassie blue, or some other 
component.
E. Effect_gf_TPI-n_and_TPIzd_gn_the_hydrglysis_gf_mygsin_by 
Çathegsin_B
It had been demonstrated previously that cathepsin B 
hydrolyzes myofibrillar proteins (Schwartz and Bird, 1977), 
Therefore, the efficiency of TPI-n and TPI-d in blocking the 
hydrolysis of myosin by cathepsin B was examined in_y^trg. 
Rabbit myosin was incubated with mouse liver cathepsin B and 
TPI-n or TPI—d in separate reaction vessels. After incubation 
for one hour at pH 5 and 37 C, the reaction products were 
analyzed by electrophoresis on a 7-18% polyacrylamide gel in 
the presence of 0.1% SDS. The results of this experiment are 
shown in Figure 10. From these data it is clear that TPI—d is 
unable to prevent the hydrolysis of myosin by cathepsin B in 
contrast to TPI-n (compare columns 6 and 7 in Fig 10). The 
arrow in Fig lO indicates the position of TPI—n and TPI-d.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
7 0
Figure 10. Effect of TPI-n and TPI-d on myosin hydrolysis by 
cathepsin B- Reaction vessels containing rabbit 
myosin (38 jjg), partially purified cathepsin B 
(16.8 milli—units), and different thiol protease 
inhibitors (46 jjg of each) in a reaction volume of 
115 ul were set up and incubated as shown below. 
Aliquots (40jjil) of each reaction were analysed on 
7—18% polyacrylamide gel slab.
Lane 1. myosin only 60 min. 37 C.
Lane 2. myosin + cathepsin B, 5 min. 37 C.
Lane 3. myosin + cathepsin B + TPI—d, O min. 37 C
Lane 4. myosin + cathepsin B + TPI-n, O min. 37 C
Lane 5. myosin + cathepsin B, 60 min. 37 C.
Lane 6. myosin + cathepsin B + TPI-d, 60 min. 37C
Lane 7. myosin + cathepsin B + TPI-n, 60 min. 37C
The protein band identified by the arrow at the 
right is the TPI protein.
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F. pH and thermal atabilitu of TPI-n
The stability of TPI-n at different pH was studied using 
cathepsin B as the test protease. When the protein was 
incubated for 1 hour in buffers at pH values ranging between 
3—10 (20 mM sodium acetate for pH range 3—5, and 20 mM sodium 
phosphate for the pH range 6—10) for 1 hour and then assayed 
at pH 6, the results shown in (Figure 11) were obtained.
These results show that the normal muscle protease inhibitor 
(TPI—n) is most stable at pH 6 and is inactive below pH 5 or 
above pH 8.0.
To determine the stability of the normal protease 
inhibitor at different temperatures, purified TPI-n was 
incubated at varying temperatures ranging from 30 C to 95 C 
for 1 hour at pH 6. The inhibitor activity remaining after 
heat treatment was examined using cathepsin B as the test 
protease in the standard reaction vessel. The results of this 
experiment are presented in Figure 12 and show that the 
inhibitor activity (TPI—n) is stable at temperatures up to 65 
C and inactivated above this temperature. Similar observations 
on pH and thermal stability have been made using rat epidermal 
thiol protease inhibitor by Takeda et al., 1983.
G" Effeçt_gf_trygsin_treatment_gn_TPI%n
The effect of trypsin on TPI—n activity was determined by 
preincubating 12 units of normal thiol protease inhibitor for 
2 hours with 10 and 20 units of trypsin in separate reaction 
Vessels. After the incubation period, 10 and 20 units of
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Figure 11. Stability of TPI—n at various pH. Purified TPI-n 
was incubated at various pH ranging from 3—10 for 
1 hour at 40 C, and then assayed for inhibitor 
activity against cathepsin B at pH 6.0 as 
described in the Methods.
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Figure 12. Thermal stability of TPI-n. Purified TPI-n was 
incubated at varying temperatures ranging from 
30 to 95 C for 1 hour at pH 6. The 
inhibitor activity remaining after the heat 
treatment was measured using cathepsin B as the 
test protease.
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soybean trypsin inhibitor were added to the reaction vessels 
to counteract the trypsin, and the remaining thiol protease 
inhibitor activity (if any) was assayed using cathepsin B as 
the test enzyme. Under these conditions no inhibitor activity 
was lost by the trypsin treatment compared to the control 
samples not treated with trypsin. Samples from similar 
reactions were analyzed using SDS—po1yaery1amide gel 
electrophoresis and high performance liquid chromatography and 
the treated TPI-n was found to be unchanged (data not shown). 
These results show that normal mouse muscle thiol protease 
inhibitor is resistant to trypsin digestion and, in this 
respect, is similar to rat skin epidermal protease inhibitor 
(Takio et al., 1984).
H. Purification of TPIs from carrier mice heterozuaous (+/dy) 
for muscular dustrophu and disease free normal retiyed 
breeders_l±/±l
The low molecular weight thiol protease inhibitor from 
carrier females (TPI—h) heterozygous for the disease, and 
disease free retired females (TPI-c) (both approximately 9 
months of age) was isolated using the same procedure as for 
the normal or dystrophic hindlimb muscle of younger mice. The 
f'esults in Table 3 show the amount of thiol protease inhibitor 
activity in hindlimb muscle of heterozygous (+/dy) and disease 
free retired breeder mice (+/+) compared to the protease 
inhibitor activity in normal and dystrophic young males (2 
months old). From these results it is clear that there is
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Iëbig__3 3 Çgn ten t_and_ i n hibi tgr_aç t^y i, ty_gf _TP 13 h_and_TP I-ç_ 
i D _ b i n d l i m b _ m u s ç l e _ ç g m g a r e d _ w i t h _ T P I % n _ a n d _ T P I - d
Source of muscle 
inhibi tor
Total protein 
content
(mg )
Total inhibitor 
activity 
(milli-units)
Speci f i c 
act ivi ty 
(units /mg 
protein)
Normal males 
(2 months old) 2.4 1203 501
Dystrophic males 
(2 months old) 2.7 891 330
Carrier females 
(9 months old) 3.4 2784 568
Normal breeders 
(9 months old) 6.2 4862 788
The above values were obtained from 5 grams wet weight of 
h indlimb.
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3 to A fold more thiol protease inhibitor in the normal 
retired females than in the normal young males. The content of 
protease inhibitor in carrier females, heterozygous for the 
disease (+/dy), also showed more inhibitor activity than 
young dystrophic males, but less activity than normal, age 
matched females. These data suggest that the inhibitor 
concentration in mouse muscle increases with age.
^• Obysical_firoBerties_of_IPlzh_and_TPI-c
The TPI-h and TPI-c preparations after the second 
Sephadex G—73 column were analysed using SDS-polyacrylamide 
gel electrophoresis, isoelectric focusing and high performance 
liquid chromatography. The migration properties of TPI—h and 
TPI—c during electrophoresis on a 7—18% gradient of 
polyacrylamide in the presence of 0.1% SDS show that only one 
polypeptide is present in each inhibitor preparation. Based 
on the migration distance of the TPI* s compared to standard 
P*"otein markers, the molecular weight was determined to be 
14,800 which is the same as that for TPI—n and TPI-d. The 
Glut ion profile of TPI—h and TPI-c from an HPLC column is 
shown in Figure 13. Only one major protein peak was detected 
in each preparation, and this protein eluted at the same 
position as TPI-n and TPI—d (see Figure 5 also).
• Effeçt_gf_TPI-h_and_TPI-ç_gn_çathegsins_Bj^_H_and_L_and 
gagain
Effect of TPI—h and TPI-c on mouse liver cathepsin B, H
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Figure 13. Chromatography of TPI-c and TPI-h on HPLC
column. lOO jig of the TPI-h and TPI-c were 
applied separately to a C— IS reverse phase column 
(Chemopack, 4.6 x 250 mm) equilibrated with 12% 
acetonitrile and 0.1% TFA. The protein was eluted 
from the column with an acetonitrile gradient as 
described in the legend to Figure 5. The actual 
tracing from the recorder is shown here including 
the column pressure curve (p) and zero voltage 
curve (V ).
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and L and papain was tested exactly as for TPI—n and TPI—d 
(see Fig. 7 and Table 2). Figure 14 shows the results of 
these experiments and Table 4 shows the IDgg values of TPI—h 
and TPI-c for the different enzymes. In all cases the IDgg 
data were found to be similar to that obtained for TPI-n 
(compare with data in Table 2).
K- Analysis_gf_TPI=h_and_TPI%ç_gn_isgeleçtriç_fgçusing_gels
To ascertain whether the inhibitor activity is associated 
with the major protein on SDS-po1yacry1amide and isoelectric 
focusing gels, 50 jag of TPI-h and TPI-c were electrophoresed 
separately on gel columns and the columns were then analyzed 
for pH, protein content and inhibitor activity as before.
With both TPI-h and TPI—c only one discrete protein band 
could be detected and these results are shown in Figure 15.
The pH at which the inhibitor protein focused was 4.5. Assays 
of the inhibitor activity in the protein extracted from the 
gels showed that, in both cases, the protein which focused at 
pH 4.5 was active against cathepsin B. However, in the TPI—h 
preparation, apart from the peak of inhibitor activity at pH 
4.5, inhibitor activity was also observed at pH 4.9 when 
papain was used as the test enzyme. This inhibitory agent, 
whatever its nature, appears to be the same component observed 
previously in muscle TPI—d preparations (see Fig. 8). Again, 
as with the protease inhibitor from dystrophic muscle, the 
inhibitor activity which focused at pH 4.9 could not be 
stained with Coomassie brilliant blue. TPI—c showed only one
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Figure 14. Effect of TPI—c and TPI—h on papain, and
cathepsins B, H and L. Varying amounts of 
inhibitor protein from carrier females (TPI-h) and 
normal female breeders (TPI—c) were added to 
separate standard reaction vessels containing the 
thiol proteases as indicated and the percent 
inhibition was determined.
#--- #, TPI—c from normal female breeders.
X---- X, TPI-h from carrier females.
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Figure 15. Isoelectric focusing of TPI—c and TPI—h on a 
polyacrylamide gel support.
Samples containing TPI—h (50 jag) or TPI—c (50 jag) 
were run on analytical isoelectric focusing gels 
and then analysed for protease inhibitor activity 
using papain (panel A and B) and cathepsin B 
(panel C and D) as test proteases. The 
photographs at the top of each panel show the 
Coomassie blue stained protein in a gel run in 
parallel compared with the pH gradient (.— .) and 
inhibitor activity in separate gels containing 
TPI—c (O — O) and TPI—h ( x— x ) .
Note: The photographs at the top each panel were
trimmed on either side because they were 10% 
longer than the gel length as shown in the diagraM*
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
87
N0I1I8IHNI iN33W3d
Hd
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
88
peak of activity, and this material coincided with the protein 
band at pH 4.5.
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IV. DISCUSSION 
It has long been established that the onset and 
progression of muscular dystrophy is associated with increased 
activity levels of several proteases, but there has been 
little agreement among researchers in the field as to the 
biochemical lesion(s) responsible for the onset of the 
disease in mammals (Ayogi et al., 1981; Wada et al., 1981; 
Perry, 1984; Sweeny and Brown, 1981). One of the theories as 
to the cause of the disease is that proteases are responsible 
for the cytoarchitectural lesions since an increase in 
protease activity has been noticed in dystrophic muscles of 
numerous animals including chickens (Ettienne et al., 1980), 
mice (Garber et al., 1980a), hamsters (Li, 1980) and humans 
(Kar and Pearson, 1976). A con comm i ten t increase in protease 
inhibitor activity has been reported in many tissues of 
diseased animals (Lenny, 1980), but the exact nature and 
source of these inhibitors has not been established.
In an earlier study we demonstrated that crude extracts 
from dystrophic mouse muscle (strain 129 ReJ/dy) contain a 
greater proportion of active to inactive thiol protease 
activity than crude extracts from normal muscle (Warner et 
al., 1983; Gopalan et al., 1986a). We suggested that enhanced 
thiol protease activity in dystrophic muscle could result from 
a lesion in one of the protease regulatory mechanisms which 
normally masks over 80% of thiol protease activity in skeletal
89
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muscle. Such a defect could account for the 4—6 fold increase 
in thiol protease activity observed in crude extracts of 
skeletal muscle in most dystrophic animals.
In the study presented here, a purification procedure 
based mainly on gel filtration columns and one which avoids a 
heat step, common1y used by other researchers was used. Since 
the latter procedure often gives rise to multiple molecular 
forms of inhibitor activity (Katanuma et al., 1983a).
Ion—exchange and papain—sepharose affinity columns were not 
used in the purification protocol as established for TPI 
purification by other researchers because considerable 
inhibitor activity was lost using these media. It is also 
known that papain-sepharose affinity columns generate 
artifacts if not used carefully (Lenney et al., 1979; Hirado 
et al., 1981 ; Katanuma et al., 1983a). Also, since it is 
known that some low molecular weight thiol protease inhibitors 
are inactive in the absence of sulfhydry1 agents, all buffers 
contained 1 mM DTT to minimize oxidation of thiol groups (if 
present) in the proteins (Kominami et al., 1982a). Thus by 
using only gel filtration chromatography, a thiol protease 
inhibitor protein has been obtained from the hindlimb muscle 
of dystrophic (TPI—d) and normal (TPI—n) males, carrier 
females heterozygous for the disease (TPI-h) and normal 
retired females (TPI—c). In all cases the purified protease 
inhibitor appears to be homogeneous by three criteria:
SDS—polyacrylamide gel electrophoresis (Fig. 3), isoelectric 
focusing (Fig 6, 15) and high performance liquid
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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chromoatography (Fig 3, 13). Furthermore, the inhibitor from
normal muscle (TPI—n), carrier females (TPI-h) and normal 
females (TPI—c) all have an IDgg (6—9 ug/ml) similar to low 
molecular weight thiol protease inhibitors from other mammals 
(Hirado et al., 1981; Kominami et al., 1982a). The major 
difference between the thiol protease inhibitor from normal 
and dystrophic muscle of the mouse is that TPI-n is active in 
the regulation of cathepsin B activity, while TPI—d is lacking 
inhibitor activity at concentrations up to 50 ug/ml. Table 2 
shows experiments using cathepsin B from both normal and 
dystrophic livers, and the results show that it is indeed the 
inhibitor which is altered in the dystrophic animal and not 
the thiol proteases because the IDgQ values for TPI-n were 
found to be the same against cathepsins B, H and L regardless 
of the source of these enzymes. Also, these results indicate 
that cathepsin B, H and L are "normal" in skeletal muscles of 
dystrophic mice.
In the study reported here, the most pure preparations of 
TPI—d showed significant activity against papain and cathepsin 
H and L, whereas it was inactive against cathepsin B. The 
nature of the inhibitor substance in TPI—d preparations 
(measured using papain) has not been determined but evidence 
suggests that it might not be protein. Thus, while the 
"apparently" homogeneous TPI-d has inhibitor activity against 
papain, cathepsins H and L, isoelectric focusing shows this 
inhibitor to be separate from the TPI—d protein. The latter 
is inactive against cathepsin B and papain after purification
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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on isoelectric focusing gels. Thus, unless isoelectric 
focusing is performed, the defect in function of TPI—d is not
apparent except in the case inhere the cathepsin B is the test
protease. In contrast to our findings with mice, Kominami and 
coworkers have found high levels of thiol protease inhibitor 
activity in extracts from dystrophic hamster muscle assayed 
using cathepsin H (Kominami et al., 1984). The apparent 
increases in TPI levels in muscle extracts of dystrophic 
hamsters may reflect a different biochemical lesion in
hamsters than in mice, since the dystrophic hamsters
(BIO-14.6) used in their experiments were from a 
cardiomyopathic line. Alternatively, the high level of TPI 
activity observed in protein preparations from these hamsters 
could be due to the use of cathepsin H as the test protease.
In crude extracts of skeletal muscle of dystrophic hamsters of 
strain Bio. 14.6, the elevated thiol protease activity appears 
to be the result of enhanced protein synthesis (Katanuma et 
al., 1983b). Perhaps in dystrophic hamsters, muscle necrosis 
occurs by a different route than in dystrophic mice.
In muscle preparations from normal mice the protease 
inhibitor of pi 4.5 (TPI-n) was found to be functional against 
papain and cathepsin B, while in muscle preparations from 
dystrophic mice the protease "inhibitor" of pi 4.5 (TPI-d) was 
non—functional against these thiol proteases (see Table 2). An 
inhibitor activity at pi 4.9 was observed in the dystrophic 
muscle which becomes detectable after isoelectric focusing of 
TPI-d. This inhibitory activity was also detected in carrier
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female mice (+/dy) heterozygous for the disease but not in 
normal retired female breeders <+/+) of the same age (Fig.
15). The source of the pi 4.9 inhibitor activity in muscle 
which is active against papain (and perhaps cathepsin H and L) 
is not known. Whatever its source, if it is a protein it has 
a high specific inhibitor activity against papain. Attempts to 
trace the origin of this inhibitor have not been made, 
however, its source could be from macrophages because 
macrophage infiltration is observed widely in diseased tissues 
(Lenney, 1980). Recently Kominami et al. (1984) demonstrated 
the presence of protease inhibitors in macrophages from 
dystrophic hamsters. It is known that while the dystrophy 
gene is expressed initially in muscle, its effects are also 
detectable in non—muscle cells such as erythrocytes, 
fibroblasts and lymphoblasts (Sweeney and Brown, 1981; Davis 
et al., 1982; Pimplikar and Malhotra, 1983). Reasons why the 
product of dystrophy gene should be manifested to a greater 
extent in muscle than in other tissues are not known. Perhaps 
in non—target tissues the dystrophy gene is inactive, while 
another gene coding for a similar protein is active. However, 
since our knowledge of the regulation of intracellular protein 
breakdown is not as advanced as our overall knowledge of 
protein synthesis, the protein catabolic mechanism may be 
regulated differently in muscle than in other tissues where 
protein turnover rates differ and the dystrophy gene product 
is of greater importance (Mil 1ward et al., 1980; Garber et 
al., 1980a). While the function of TPI’s in healthy
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individuals is not clearly understood (Dean, 1979), it is 
possible that TPI’s normally function by protecting the cell 
from inappropriate intracellular proteolysis.
It is not known whether the thiol proteases that damage 
the structural and soluble components of the myotubes and 
other cells are cytosolic or lysosomal in origin, but at least 
one report indicates that lysosomes from dystrophic animals 
have altered membrane properties which may allow some 
lysosomal thiol proteases to leak into the cytosol in 
dystrophic but not normal individuals (Davis et al., 1982). 
Circulating macrophages and other protease rich cells 
(fibroblasts) in muscle may also contribute proteases to cells 
lacking functional TPI’s compounding the problem for myoblasts 
and myotubes in dystrophic animals (Kar and Pearson, 1978).
In this study it is assumed that the TPI isolated from the 
whole muscle is myocytic in origin. Evidence from other 
workers has shown that thiol protease inhibitors in muscle are 
located mainly in the cytosol of post—fusion myoblasts 
(myotubes) and not in fat or connective tissue cells (Lenny, 
1980).
That muscular dystrophy in most animals appears to be 
closely linked to a defect in the protease regulatory 
mechanism is a view supported by several studies using 
protease inhibitors. Libby and Goldberg (1978) and Sher et 
al. (1981 ) have shown that leupeptin, a thiol protease 
inhibitor, significantly reduces the rate of protein 
degradation in mice with hereditary muscular dystrophy, while
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McGowan et al. (1976) and Stracher et al. (1978; 1979) made 
similar observations using muscle and cells from dystrophic 
chickens. However, Hudecki et al. (1981) were unable to 
observe any beneficial effects of leupeptin on dystrophic 
chickens. Recently Tsuji and Matsushita (1986) have shown 
beneficial effects of bestatin, a diaminopeptidase inhibitor, 
on dystrophic mice with elevated levels of diaminopeptidases. 
(The exact role of diaminopeptidases in myofibrillar protein 
turnover is, however, not understood). Bestatin is a small 
molecular weight immunomodifier originally isolated from 
Stregtgmyces_giivgretivuii. It is known to have a potent 
inhibitor effect on aminopeptidase B and leucine 
aminopeptidase existing exclusively in the cell membrane, and 
to attach to the cell membrane of macrophages, T-lymphocytes 
and other mammalian cells and modify their functions (Muller 
et al., 1982). If immunological deficiencies play a major 
role in the pathology of muscular dystrophy, then it may be 
that the immuno—potentiating action of bestat in is conducive 
to controlling the disease process. Thus despite certain 
equivocal data on the effectiveness of protease inhibitors in 
dystrophic animals, it appears that lysosomal proteases, 
especially the thiol proteases, play a key role in the onset 
and progression of muscle degeneration in dystrophic animals. 
The observations made in this study show that the TPI in 
dystrophic mouse muscle is functionally defective supports 
this conclusion.
The reason(s) for the loss of activity in the TPI protein
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of skeletal nxascle of dystrophic mice is not yet known. It 
may be due to an amino acid substitution in TPI—n which 
affects the molecular conformation of the protein, but not its 
pi, or it may be due to a post—translational modification of 
one or more amino acids in the molecule. Recent data from an 
amino acid analyses of the TPI protein carried out in 
collaboration with Dr. M. Bloom at the University of Toronto 
have shown one less tyrosine residue and one or two fewer 
histidine residues in TPI-d compared to TPI-n. Also, there 
are two additional lysine residues in TPI-d compared to 
TPI-n. The N—terminal amino acids are blocked in both TPI-n 
and TPI—d. Since both TPI-n and TPI-d resist hydrolysis by 
trypsin at high enzyme to substrate ratios (1:20) and long 
incubation periods (48 hours at 37 C), comparative analysis of 
the tryptic fragments of the TPI’s have not been carried out. 
Also, glycoprotein analyses were negative for both TPI-n and 
TPI-d which indicate that the differences in inhibitor 
activity are not due to differences in their carbohydrate 
moiety. Structural studies, including amino acid sequence 
analyses to identify the altered or missing amino acid(s) in 
the TPI of animals with hereditary muscular dystrophy remain 
to be done.
The appearance of inhibitor activity at pi 4.9 in 
extracts from skeletal muscles of carrier females heterozygous 
for the disease opens up the possibility for carrier 
detection, since carrier detection of Duchenne muscular 
dystrophy is still a significant problem (Garden—Medwin, 1983;
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Dubowitz, 1982). Despite the introduction of new techniques 
with more or less success, a significant percent of carriers 
remain without diagnosis and, consequently, the disease goes 
on being transmitted. The introduction recently of a 
radioimmunoassay for serum myoglobin has opened up new 
perspectives for the detection of carriers with muscular 
dystrophy because "leaky" plasma membranes in patients and 
carriers would allow abundant loss of myoglobin from the 
skeletal muscles into serum. This assay has been used as an 
alternative to the use of creatine kinase for carrier 
detection (Sabria—Lea1, 1986). However, this assay is not
unique to muscular dystrophy because myoglobin release into 
serum has been observed also in myocardial infarction 
(Adornato et al., 1978). The findings described in this 
dissertation for dystrophic mice may serve as a model for 
human muscular diseases including Duchenne muscular dystrophy 
and if so, an effective assay may be developed to screen 
potential carriers of the disease for the presence of either 
the defective TPI or the pi 4.9 inhibitor component in muscle 
extracts.
Recent reports on the isolation of portions of Duchenne 
muscular dystrophy gene (Monaco et al., 1986; Worton et al., 
1984) are also important and relevant to the problem at hand. 
Although the product(s) of the cloned gene fragments have not 
been identified, it will be interesting to see whether the 
defective gene in Duchenne muscular dystrophy codes for a 
protease inhibitor as suggested by the work in this
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)8
dissertation.
As the amino acid sequence data of mouse muscle TPI—d 
become available, labelled DNA probes can be constructed
to detect and isolate the dystrophic and normal genes from 
restriction enzyme digests of genomic DNA. The desired 
restriction fragments can then be cloned in a suitable 
phage/piasmid system. The nucleotide sequence of the cloned 
(defective and normal) genes would help to identify the 
altered/missing nucleotide(s) in the dystrophy gene, and allow 
in_si,tu hybridization to localize the TPI gene.
Muscular dystrophy in mice of strain 129/ReJ(dy/dy) is a 
disease transmitted by a single autosomal recessive factor 
(West and Murphy, 1960). However, in many of its clinical 
features it resembles the Duchenne form of muscular dystrophy 
(DMD) affecting human males. Thus if the TPI gene in 
dystrophic mice is functionally inactive or defective, the 
primary lesion causing the onset and progression of the 
Duchenne form of muscular dystrophy in humans might be 
(similar or identical) to the one in mice. The significance 
of the findings reported in this dissertation have enhanced 
our understanding of the biochemical basis of muscular 
dystrophy to the point where a cure for the disease may be in 
sight. Should future research on dystrophic muscle in humans 
reveal a defect in the TPI protein similar to that found in 
mice, then a major effort should be mounted to develop and 
test additional protease inhibitors in search of a treatment 
to ameliorate this debilitating disease until such time as the
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frequency of the disease in humans can be reduced to the 
lowest level possible or the disease eliminated completely.
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